Literature DB >> 23001426

Refining the phenotype associated with MEF2C point mutations.

Thierry Bienvenu1, Bertrand Diebold, Jamel Chelly, Bertrand Isidor.   

Abstract

Up to now, only five-point mutations in the MEF2C gene have been described in patients with severe mental retardation with absent speech, limited walking abilities, epilepsy, and lack of gross malformations. In brain, MEF2C is essential for early neurogenesis, neuronal migration, and differentiation. Here, we present a new patient with severe mental retardation, epilepsy, and hand stereotypies associated with a novel MEF2C frameshift mutation c.457delA. The purpose of this work was to clarify criteria for the selection of patients with severe intellectual disability to screen for deficiency in the MEF2C gene. By combining the clinical data of all patients with MEF2C point mutations published so far with the phenotype of our patient, a targeted search for MEF2C mutations could be applied to patients with a severe intellectual deficiency associated with absence of language and hypotonia, strabismus, and epilepsy (started after 6 months, often well controlled by valproate).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23001426     DOI: 10.1007/s10048-012-0344-7

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  12 in total

1.  MEF2C mutations are a rare cause of Rett or severe Rett-like encephalopathies.

Authors:  L Lambert; T Bienvenu; L Allou; M Valduga; B Echenne; B Diebold; C Mignot; D Héron; V Roth; A Saunier; A Moustaïne; P Jonveaux; C Philippe
Journal:  Clin Genet       Date:  2012-03-26       Impact factor: 4.438

2.  Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression.

Authors:  Markus Zweier; Anne Gregor; Christiane Zweier; Hartmut Engels; Heinrich Sticht; Eva Wohlleber; Emilia K Bijlsma; Susan E Holder; Martin Zenker; Eva Rossier; Ute Grasshoff; Diana S Johnson; Lisa Robertson; Helen V Firth; Arif B Ekici; André Reis; Anita Rauch
Journal:  Hum Mutat       Date:  2010-06       Impact factor: 4.878

3.  Transcription factor 4 and myocyte enhancer factor 2C mutations are not common causes of Rett syndrome.

Authors:  Roksana Armani; Hayley Archer; Angus Clarke; Pradeep Vasudevan; Christiane Zweier; Gladys Ho; Sarah Williamson; Desiree Cloosterman; Nan Yang; John Christodoulou
Journal:  Am J Med Genet A       Date:  2012-03-01       Impact factor: 2.802

4.  De novo 5q14.3 translocation 121.5-kb upstream of MEF2C in a patient with severe intellectual disability and early-onset epileptic encephalopathy.

Authors:  Hirotomo Saitsu; Noboru Igarashi; Mitsuhiro Kato; Ippei Okada; Tomoki Kosho; Osamu Shimokawa; Yuki Sasaki; Kiyomi Nishiyama; Yoshinori Tsurusaki; Hiroshi Doi; Noriko Miyake; Naoki Harada; Kiyoshi Hayasaka; Naomichi Matasumoto
Journal:  Am J Med Genet A       Date:  2011-10-11       Impact factor: 2.802

5.  Phosphorylation of the MADS-Box transcription factor MEF2C enhances its DNA binding activity.

Authors:  J D Molkentin; L Li; E N Olson
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

6.  The MEF2C-Related and 5q14.3q15 Microdeletion Syndrome.

Authors:  M Zweier; A Rauch
Journal:  Mol Syndromol       Date:  2012-04-16

7.  MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations.

Authors:  N Le Meur; M Holder-Espinasse; S Jaillard; A Goldenberg; S Joriot; P Amati-Bonneau; A Guichet; M Barth; A Charollais; H Journel; S Auvin; C Boucher; J-P Kerckaert; V David; S Manouvrier-Hanu; P Saugier-Veber; T Frébourg; C Dubourg; J Andrieux; D Bonneau
Journal:  J Med Genet       Date:  2009-07-09       Impact factor: 6.318

8.  Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion.

Authors:  C Cardoso; A Boys; E Parrini; C Mignon-Ravix; J M McMahon; S Khantane; E Bertini; E Pallesi; C Missirian; O Zuffardi; F Novara; L Villard; S Giglio; B Chabrol; H R Slater; A Moncla; I E Scheffer; R Guerrini
Journal:  Neurology       Date:  2008-12-10       Impact factor: 9.910

9.  De novo microdeletion of 5q14.3 excluding MEF2C in a patient with infantile spasms, microcephaly, and agenesis of the corpus callosum.

Authors:  Keiko Shimojima; Akihisa Okumura; Harushi Mori; Shinpei Abe; Mitsuru Ikeno; Toshiaki Shimizu; Toshiyuki Yamamoto
Journal:  Am J Med Genet A       Date:  2012-07-27       Impact factor: 2.802

10.  A novel microdeletion syndrome involving 5q14.3-q15: clinical and molecular cytogenetic characterization of three patients.

Authors:  Hartmut Engels; Eva Wohlleber; Alexander Zink; Juliane Hoyer; Kerstin U Ludwig; Felix F Brockschmidt; Dagmar Wieczorek; Ute Moog; Birgit Hellmann-Mersch; Ruthild G Weber; Lionel Willatt; Martina Kreiss-Nachtsheim; Helen V Firth; Anita Rauch
Journal:  Eur J Hum Genet       Date:  2009-05-27       Impact factor: 4.246

View more
  28 in total

Review 1.  The Impact of Next-Generation Sequencing on the Diagnosis and Treatment of Epilepsy in Paediatric Patients.

Authors:  Davide Mei; Elena Parrini; Carla Marini; Renzo Guerrini
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

2.  AlzBase: an Integrative Database for Gene Dysregulation in Alzheimer's Disease.

Authors:  Zhouxian Bai; Guangchun Han; Bin Xie; Jiajia Wang; Fuhai Song; Xing Peng; Hongxing Lei
Journal:  Mol Neurobiol       Date:  2014-11-29       Impact factor: 5.590

3.  MEF2C Haploinsufficiency features consistent hyperkinesis, variable epilepsy, and has a role in dorsal and ventral neuronal developmental pathways.

Authors:  Alex R Paciorkowski; Ryan N Traylor; Jill A Rosenfeld; Jacqueline M Hoover; Catharine J Harris; Susan Winter; Yves Lacassie; Martin Bialer; Allen N Lamb; Roger A Schultz; Elizabeth Berry-Kravis; Brenda E Porter; Marni Falk; Anu Venkat; Rena J Vanzo; Julie S Cohen; Ali Fatemi; William B Dobyns; Lisa G Shaffer; Blake C Ballif; Eric D Marsh
Journal:  Neurogenetics       Date:  2013-02-07       Impact factor: 2.660

Review 4.  Involvement of cortical fast-spiking parvalbumin-positive basket cells in epilepsy.

Authors:  X Jiang; M Lachance; E Rossignol
Journal:  Prog Brain Res       Date:  2016-06-07       Impact factor: 2.453

5.  Evolution of Osteocrin as an activity-regulated factor in the primate brain.

Authors:  Bulent Ataman; Gabriella L Boulting; David A Harmin; Marty G Yang; Mollie Baker-Salisbury; Ee-Lynn Yap; Athar N Malik; Kevin Mei; Alex A Rubin; Ivo Spiegel; Ershela Durresi; Nikhil Sharma; Linda S Hu; Mihovil Pletikos; Eric C Griffith; Jennifer N Partlow; Christine R Stevens; Mazhar Adli; Maria Chahrour; Nenad Sestan; Christopher A Walsh; Vladimir K Berezovskii; Margaret S Livingstone; Michael E Greenberg
Journal:  Nature       Date:  2016-11-10       Impact factor: 49.962

Review 6.  Further Clinical Delineation of the MEF2C Haploinsufficiency Syndrome: Report on New Cases and Literature Review of Severe Neurodevelopmental Disorders Presenting with Seizures, Absent Speech, and Involuntary Movements.

Authors:  Irena Vrečar; Josie Innes; Elizabeth A Jones; Helen Kingston; William Reardon; Bronwyn Kerr; Jill Clayton-Smith; Sofia Douzgou
Journal:  J Pediatr Genet       Date:  2017-04-12

7.  MEF2D drives photoreceptor development through a genome-wide competition for tissue-specific enhancers.

Authors:  Milena M Andzelm; Timothy J Cherry; David A Harmin; Annabel C Boeke; Charlotte Lee; Martin Hemberg; Basil Pawlyk; Athar N Malik; Steven W Flavell; Michael A Sandberg; Elio Raviola; Michael E Greenberg
Journal:  Neuron       Date:  2015-03-19       Impact factor: 17.173

8.  Genome-Wide DNA Methylation Patterns Analysis of Noncoding RNAs in Temporal Lobe Epilepsy Patients.

Authors:  Wenbiao Xiao; Yuze Cao; Hongyu Long; Zhaohui Luo; Shuyu Li; Na Deng; Jianjian Wang; Xiaoyan Lu; Tianfeng Wang; Shangwei Ning; Lihua Wang; Bo Xiao
Journal:  Mol Neurobiol       Date:  2017-01-05       Impact factor: 5.590

9.  Antagonizing Increased miR-135a Levels at the Chronic Stage of Experimental TLE Reduces Spontaneous Recurrent Seizures.

Authors:  Vamshidhar R Vangoor; Cristina R Reschke; Ketharini Senthilkumar; Lieke L van de Haar; Marina de Wit; Giuliano Giuliani; Mark H Broekhoven; Gareth Morris; Tobias Engel; Gary P Brennan; Ronan M Conroy; Peter C van Rijen; Peter H Gosselaar; Stephanie Schorge; Roel Q J Schaapveld; David C Henshall; Pierre N E De Graan; R Jeroen Pasterkamp
Journal:  J Neurosci       Date:  2019-04-23       Impact factor: 6.167

10.  Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/β-catenin signaling.

Authors:  X L Bai; Q Zhang; L Y Ye; F Liang; X Sun; Y Chen; Q D Hu; Q H Fu; W Su; Z Chen; Z P Zhuang; T B Liang
Journal:  Oncogene       Date:  2014-10-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.